2022 full-year results and business update 15
Category: 2023
Transgene to Present Multiple Posters Highlighting the Potential of its Exciting Immunotherapy Pipeline at AACR 2023
Transgene to present multiple posters highlighting the potential of its exciting immunotherapy pipeline at AACR2023 15
Transgene Appoints John C. Bell and Pedro Romero as Key Scientific Advisors
Transgene appoints John C Bell and Pedro Romero as Key Scientific advisors 15
Transgene Receives Approval to Start a Phase I Trial of TG6050, a Novel IL-12-Armed Oncolytic Virus Given by Intravenous Administration
Transgene recieves approval to start a Phase I trial of TG6050 15
Transgene announces Financial Calendar for 2023
Transgene announces Financial Calendar for 2023 15
